|Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5, 1-d]-1, 2, 3, 5-tetrazin-4 (3H)-one (CCRG 81045; M & B 39831), a novel drug with potentialá…|
MFG Stevens, JA Hickman, SP Langdon, D Chubb, L Vickers, R Stone, ...
Cancer research 47 (22), 5846-5852, 1987
|Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer|
SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ...
Breast Cancer Research 15 (5), 1-37, 2013
|Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis|
SV Rajkumar, RA Mesa, R Fonseca, G Schroeder, MF Plevak, ...
Clinical cancer research 8 (7), 2210-2216, 2002
|Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma|
W Sakai, EM Swisher, C Jacquemont, KV Chandramohan, FJ Couch, ...
Cancer research 69 (16), 6381-6386, 2009
|Characterization and properties of nine human ovarian adenocarcinoma cell lines|
SP Langdon, SS Lawrie, FG Hay, MM Hawkes, A McDonald, IP Hayward, ...
Cancer research 48 (21), 6166-6172, 1988
|The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.|
JM Bartlett, SP Langdon, BJ Simpson, M Stewart, D Katsaros, P Sismondi, ...
British journal of cancer 73 (3), 301, 1996
|Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system|
A Koussounadis, SP Langdon, IH Um, DJ Harrison, VA Smith
Scientific reports 5, 10775, 2015
|Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases|
SJ Aitken, JS Thomas, SP Langdon, DJ Harrison, D Faratian
Annals of Oncology 21 (6), 1254-1261, 2010
|Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor–positive patients|
JF Smyth, C Gourley, G Walker, MJ MacKean, A Stevenson, ...
Clinical Cancer Research 13 (12), 3617-3622, 2007
|Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab|
D Faratian, A Goltsov, G Lebedeva, A Sorokin, S Moodie, P Mullen, C Kay, ...
Cancer research 69 (16), 6713-6720, 2009
|Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo|
T Sethi, S Langdon, J Smyth, E Rozengurt
Cancer Research 52 (9 Supplement), 2737s-2742s, 1992
|New strategies for targeting the hypoxic tumour microenvironment in breast cancer|
C Ward, SP Langdon, P Mullen, AL Harris, DJ Harrison, CT Supuran, ...
Cancer treatment reviews 39 (2), 171-179, 2013
|Estrogen receptor-α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen|
AJM O’Donnell, KG Macleod, DJ Burns, JF Smyth, SP Langdon
Endocrine-related cancer 12 (4), 851-866, 2005
|CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup|
A Bowman, H Gabra, SP Langdon, A Lessells, M Stewart, A Young, ...
Clinical cancer research 8 (7), 2233-2239, 2002
|Expression of the heat shock protein HSP27 in human ovarian cancer.|
SP Langdon, GJ Rabiasz, GL Hirst, RJ King, RA Hawkins, JF Smyth, ...
Clinical Cancer Research 1 (12), 1603-1609, 1995
|Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma|
SL Cooke, CKY Ng, N Melnyk, MJ Garcia, T Hardcastle, J Temple, ...
Oncogene 29 (35), 4905-4913, 2010
|Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer|
K Macleod, P Mullen, J Sewell, G Rabiasz, S Lawrie, E Miller, JF Smyth, ...
Cancer research 65 (15), 6789-6800, 2005
|High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer|
HR Hendriks, HH Fiebig, R Giavazzi, SP Langdon, JM Jimeno, ...
Annals of Oncology 10 (10), 1233-1240, 1999
|Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo|
S Langdon, T Sethi, A Ritchie, M Muir, J Smyth, E Rozengurt
Cancer research 52 (16), 4554-4557, 1992
|Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study|
E Boven, B Winograd, DP Berger, MP Dumont, BJM Braakhuis, ě Fodstad, ...
Cancer research 52 (21), 5940-5947, 1992